Characterization of human TSE strains after passage in humanized transgenic mice by Galeno Roberta
 
 
UNIVERSITÀ DEGLI STUDI DI VERONA 
 
 
SCUOLA DI DOTTORATO IN SCIENZE  
DELLA VITA E DELLA SALUTE 
 
DOTTORATO DI RICERCA IN BIOTECNOLOGIE MOLECOLARI, 
INDUSTRIALI ED AMBIENTALI 
CICLO XXII  
 
 
 
Characterization of human TSE strains after passage in humanized 
transgenic mice 
 
 
 
Dottoranda: Roberta Galeno 
 
 
 
 
 
 
 
 
 
Coordinatore: Prof. Roberto Bassi   
 
Tutor: Prof. Salvatore Monaco 
 
Tutor esterni: Dott. Franco Cardone 
 Prof. Maurizio Pocchiari 
 
 
 
 
 
 
 2 
Index 
 
ABBREVIATIONS ............................................................................................................................ 3 
1. INTRODUCTION .......................................................................................................................... 5 
1.  1   TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHIES ............................................ 5 
1.  2   THE GENE PRNP AND THE PROTEIN PrP ...................................................................... 8 
1.  3   THE ETIOLOGICAL AGENT OF TSEs ............................................................................ 11 
1.  4   TSE STRAINS ..................................................................................................................... 12 
1.  5   EXPERIMENTAL TRANSMISSION STUDIES AND THE SPECIES BARRIER .......... 16 
1.  6   SPORADIC CJD .................................................................................................................. 17 
1.  7   sCJD TRANSMISSION AND TRANSGENIC HUMANIZED MICE .............................. 20 
2. AIM OF THE STUDY ................................................................................................................. 23 
3. METHODS ................................................................................................................................... 24 
3.  1   ANIMALS ........................................................................................................................... 24 
3.  1.1   Transgenic mice ............................................................................................................ 24 
3.  1.2   Confirmation of the genotype of the transgenic mice ................................................... 24 
3.  2   INOCULATION OF THE TRANSGENIC MICE .............................................................. 27 
3.  2.1   Sporadic CJD patients ................................................................................................... 27 
3.  2.2   Preparation of inocula from human brains .................................................................... 28 
3.  2.3   Inoculation of mice ....................................................................................................... 29 
3.  3   EXAMINATION OF INOCULATED MICE ..................................................................... 29 
3.  3.1   Clinical signs ................................................................................................................. 29 
3.  3.2   Survival time ................................................................................................................. 30 
3.  3.3   Histological and immunohistochemical examination ................................................... 30 
3.  3.4   Preparation of the brain tissue for the Western blot analysis ........................................ 32 
3.  3.5   PrP
TSE
 detection by Immunoblot ................................................................................... 33 
4. RESULTS ..................................................................................................................................... 35 
4.  1   ATTACK RATE .................................................................................................................. 35 
4.  2   SURVIVAL TIME ............................................................................................................... 36 
4.  3   TOPOGRAPHY OF SPONGIOSIS AND PrP
TSE
 DEPOSITION ....................................... 40 
4.  4   PrP
TSE 
GLYCOTYPE ............................................................................................................ 50 
5. DISCUSSION ............................................................................................................................... 52 
6. CONCLUSIONS .......................................................................................................................... 58 
7. BIBLIOGRAPHY ........................................................................................................................ 60 
ACKNOWLEDGEMENTS............................................................................................................. 70 
 
 
 3 
 
ABBREVIATIONS 
aa: Amino acids 
Ala: Alanine 
BSE: Bovine spongiform encephalopathy 
CJD: Creutzfeldt-Jakob disease 
CNS: Central nervous system 
CWD: Chronic wasting disease 
DTT: Dithiothreitol 
DW: Drowsy 
EEG: Electroencephalogram 
FFI: Fatal Familial Insomnia 
FTIR: Fourier transformed infrared spectroscopy 
G: Gauge 
GPI: Glycosylphosphatidylinositol 
GSS: Gerstmann-Sträussler-Scheinker disease 
GT: Gene targeting 
H&E: Haematoxylin-eosin staining 
HuTg: Transgenic mice expressing human PrP 
HuMM: Transgenic mice expressing human PrP with methionine/methionine genotype at codon 
129 
HuMV: Transgenic mice expressing human PrP with methionine/valine genotype at codon 129 
HuVV: Transgenic mice expressing human PrP with valine/valine genotype at codon 129 
HY: Hyper 
Iso: Isoleucine 
kDa: kiloDalton 
LDS: Lithium dodecylsulphate 
mAb: Monoclonal antibody 
MM: Methionine/methionine 
MV: Methionine/valine 
NGS: Normal goat serum 
NMR: Nuclear magnetic resonance 
PBS: Phosphate buffered saline 
PCR: Polymerase chain reaction 
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PK: Proteinase K 
PRNP: Human gene encoding the prion protein 
prnp: Mouse gene encoding the prion protein 
PrP: Prion protein  
PrP
C
: Cellular prion protein 
PrP
TSE
: Pathological isoform of prion protein 
RGI: Random genomic insertion 
sCJD: Sporadic Creutzfeldt-Jakob disease 
vCJD: Variant Creutzfeldt-Jakob disease 
SDS: Sodium dodecylsulphate 
SD: Standard deviation 
TBS: Tris buffered saline 
TBST: TBS/Tween 20 
Thr: Threonine 
TME: Transmissible mink encephalopathy 
TSE: Transmissible spongiform encephalopathy 
Val: Valine 
VV: Valine/valine 
WB: Western blot 
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1. INTRODUCTION 
1.  1   TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHIES 
Transmissible Spongiform Encephalopathies (TSEs) are fatal neurodegenerative diseases affecting 
human and animals, caused by an infectious agent whose nature is still under debate. The main 
event characterizing TSEs is the accumulation in the Central Nervous System (CNS) of insoluble 
fibrils mainly composed of the disease-associated isoform of the host prion protein (PrP
TSE
), which 
is produced following a conformational change from the endogenous cellular prion protein (PrP
C
) 
(Prusiner, 1998). PrP
TSE
 fibrils can sometimes aggregate into amyloid plaques that are easily 
detectable by conventional neurohistological examinations, together with other TSE-specific lesions 
such as spongiosis (i.e. a sponge-like vacuolation of cerebral grey matter), neuron loss, and gliosis 
(figure 1. 1). Pathological misfolding of host proteins links TSEs to other human neurodegenerative 
diseases like Alzheimer‟s disease (Amyloid ), Parkinson‟s disease (-synuclein), or Huntington‟ s 
disease (huntingtin). Among these however, only TSEs have been proved to be transmissible either 
naturally (human to human through medical procedures, or animal to animal via natural secretions), 
or experimentally (to laboratory animals) via different routes of infection. 
According to their origin, human TSEs are classified as sporadic, inherited, or infectious forms 
(Ironside, 1998) (table 1. 1). Sporadic forms (including the vast majority of human TSE cases), 
occur without any apparent episode of infection and are mainly represented by sporadic Creutzfeldt-
Jakob disease (CJD), a rapidly progressive dementia commonly associated with myoclonic jerks, 
pyramidal, extrapyramidal, and cerebellar signs. 
Inherited forms, accounting for 10-15% of human cases, are associated to mutations (more than 50 
have been described until now) of the prion protein gene (PRNP) and, besides a typical Creutzfeldt-
Jakob disease picture, they may manifest as peculiar clinical and pathological syndromes (e.g. Fatal 
Familial Insomnia, FFI, Gerstmann-Sträussler-Scheinker disease, GSS). 
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Infectious forms reported in the literature originated after accidental inter-human transmission of 
the infectious agent by medical procedures or have a zoonotic origin through contaminated food.  
Animal TSEs include scrapie of sheep and goats (Hunter et al., 2000), a disease already reported in 
the eighteenth century (Schneider et al., 2008) and the first TSE described (by McGowan in 1922). 
Other animal TSEs include: chronic wasting disease (CWD) of deer and elk (Williams, 2005), the 
transmissible mink encephalopathy (TME) (Libersky et al., 2009) and bovine spongiform 
encephalopathy (BSE) (Wells et al., 1991) which reached an epidemic diffusion during the end of 
the last century and transmitted to humans, as variant CJD (vCJD), by ingestion of contaminated 
food (Will et al., 1996). 
Despite intensive studies conducted during the last 50 years, many aspects of TSE diseases are still 
obscure such as the nature of the etiological agent, the molecular mechanism of prion propagation 
and replication, the neurodegeneration caused by PrP
TSE
 accumulation in the brain, and the wide 
phenotypic spectrum observed even among the same forms of TSEs disease. 
 
 
 
Table 1. 1: Spectrum of human prion diseases (modified from Aguzzi et al., 2004). 
Form Prion disease Etiology 
Sporadic 
Sporadic Creutzfeldt-Jakob disease (sCJD) 
Sporadic Fatal Insomnia 
Unknown 
Inherited 
Genetic CJD 
PRNP mutation Fatal Familial Insomnia (FFI) 
Gerstmann-Sträussler-Scheinker disease (GSS) 
Infective 
Iatrogenic CJD Surgical procedure 
Variant CJD 
Cattle to human via BSE-
contaminated food; 
Human to human via blood 
transfusion  
Kuru Ritualistic cannibalism 
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Figure 1. 1. Histological alterations observed in a CJD patient‟s brain. (a) spongiform degeneration; (b) 
PrP
TSE
 deposition; (c) gliosis. 
 
   A 
   B 
            C 
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1.  2   THE GENE PRNP AND THE PROTEIN PrP 
PrP
TSE
 is the pathological isoform of the host-encoded cellular prion protein PrP
C
, a glycosyl-
phosphatidylinositol (GPI) membrane-anchored glycoprotein of about 33-35 kDa. The protein is 
encoded by the PRNP gene, placed on the short arm of chromosome 20 in humans (Makrinou et al., 
2002). 
More than thirty point mutations and several insertions encoding additional copies of an 
octapeptide, regularly present in five copies on PRNP, are linked to the genetic forms of human 
TSEs (Kovács et al., 2005). Moreover, although different polymorphisms of PRNP have been 
discovered, only the methionine/valine (M/V) polymorphism at codon 129 has shown a critical 
influence on clinical, pathological and biochemical phenotype of human TSE diseases. It has also a 
role in the susceptibility to the disease (Pocchiari et al., 2004) (figure 1. 2): CJD mainly affects 
homozygous subjects, especially for methionine, while 129 heterozygosity seems to have a 
protective effect (Puopolo et al., 2003). Indeed 80% of patients with sCJD and 100% of patients 
with vCJD were homozygous for the methionine at codon 129 (Ironside et al., 2004; Alperovitch et 
al., 1999). 
 
 
Figure 1. 2.  Mutations and polymorphisms of the prion protein associated with human TSEs (from Wadsworth et al., 
2003). 
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Human PrP
C
 consists of 253 amino acids (aa) and its tridimensional structure, inferred by nuclear 
magnetic resonance (NMR) studies (Zahn et al., 2000) on recombinant, non glycosylated forms, 
consists of a long, unstructured, N-terminal domain of about 100 aa that starts with a signal peptide 
(aa 1-22) that targets the protein to the cell surface (Turk et al., 1988), followed by five repeats of a 
copper binding octapeptide (Viles et al., 1999). The C-terminal domain, highly conserved over 
many different species, consists of two short antiparallel beta-sheets and three long alpha-helices 
with a disulfide bridge (cysteine 179 and 214) between helix 2 and 3 (Haire et al., 2004) and a GPI 
anchor (aa 230) that binds the protein to the raft domains on the cell surface (Naslavsky et al., 
1997). PrP
C
 undergoes facultative N-glycosylation at two sites (aa 181 and 196), resulting in 
unglycosylated, monoglycosylated, and diglycosylated forms (figure 1. 3) (Endo et al., 1989; 
Bolton et al., 1985). This basic structure was confirmed by studies on a wide range of mammalian 
species (Cappai et al., 2004; Riesner, 2003). 
 
 
 
Figure 1. 3. Human cellular prion protein. 
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PrP
C
 is expressed in a wide range of tissues including CNS (mainly in neurons and glia), blood 
cells, lymphatic tissue, intestine, muscles, lungs, spleen and heart (Shmakov et al., 2000). The 
physiological role of PrP
C
 is still under debate. Several functions have been attributed to this protein 
ranging from signal transduction, antioxidant activity, cell membrane signaling, cell adhesion, 
synaptic transmission, to regulation of immune system and immune response as well as pro-
apoptotic or anti-apoptotic activity (Sauer et al., 2003; Gauczynski et al., 2001; White et al., 1999). 
The presence of PrP
C
 is not essential for survival (Wopfner et al., 1999; Manson et al., 1994; Büeler 
et al., 1992), but it is necessary for replication of the TSEs infectious agent and neurotoxicity to 
occur (Collinge et al., 2007; Mallucci et al., 2005). The close relationship between infection and 
expression of PrP
C
 in the host is clearly highlighted in knock-out mice for PrP gene (genotype 
prnp
0/0
), which are resistant to the experimental infection with scrapie (Büeler et al., 1993). 
PrP
C
 and PrP
TSE 
share the same amino acidic sequence and undergo to the same post-translational 
modifications (Harris et al., 2003), but differ profoundly in their conformation, that is accounted for 
their different biochemical and biophysical properties (Pan et al., 1993; Safar et al., 1993; Caughey 
et al., 1991). PrP
C
 is monomeric, proteinase-sensitive and soluble in non-ionic detergents, whereas 
PrP
TSE 
is insoluble, hydrophobic, and partially resistant to proteinase and tends to aggregate. Indeed 
proteinase K (PK) digestion of PrP
TSE 
originates a proteinase-resistant core with molecular weight 
of 27-30 kDa, which retains the full infectivity (Prusiner et al., 1984; Bolton et al., 1982). The 
insolubility of PrP
TSE 
in physiological solutions and its aggregated state hamper the definition of its 
tridimensional structure by high-resolution techniques. Low-resolution optical spectroscopic 
measurements revealed that PrP
TSE 
contains mostly beta-sheet structures (figure 1. 4) (Caughey et 
al., 2001; Pan et al., 1993), suggesting that the differences between the two isoforms result from 
their distinct conformations. 
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Figure 1. 4. Tridimensional structure of mature PrPC obtained by NMR and presumable tridimensional structure of 
PrP
TSE
. 
 
 
 
 
 
 
 
 
 
 
1.  3   THE ETIOLOGICAL AGENT OF TSEs 
One of the unsolved issues of prion diseases is the definition of the nature of the etiological agent 
responsible for the pathology. Originally it was defined as a “slow unconventional virus” 
(Gajdusek, 1977) because of its viral size, peculiar biological properties (i.e. high resistance to 
inactivation and apparent absence of a nucleic acid), transmissibility, and the long incubation time 
that characterizes the disease. However, the failure to identify a TSE-specific nucleic acid despite 
uncountable efforts together with the identification of an insoluble and proteinase-resistant protein 
(PrP
TSE
) associated with infectious brain material and the highly unusual resistance to treatments 
that inactivate viruses or naked nucleic acids (e.g. heating, gamma radiations, nuclease) (Taylor, 
2000; Alper, 1993), led to the genesis of the “protein only hypothesis” (Griffith, 1967). This 
atypical agent was defined by Prusiner as “prion” (proteinaceous infectious only particle) (Prusiner, 
1982), to distinguish it from other infectious agent like virus or viroids. Prion particles are credited 
to be devoid of nucleic acid and to propagate in the host by directing the refolding of the 
PrP
C 
PrP
TSE 
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physiological PrP
C
 protein into the PrP
TSE
 conformation through an autocatalytic process which is 
still matter for speculation (Morris et al., 2009). 
The “prion only” hypothesis is a reliable model to explain a number series of observations like the 
correlation between PRNP gene mutations and genetic TSEs (Gabizon et al., 1996), the strictly 
association between infectivity and PrP
TSE 
(Gabizon et al., 1988), the finding that PrP knockout 
mice do not develop the disease (Büeler et al., 1993) and the absence of a specific immune response 
in the infected host (Berg et al., 1994; Casaccia et al., 1989).  
On the other hand, a growing amount of data suggests that TSE infectivity can be separated from 
PrP
TSE
 (Barron et al., 2007; Piccardo et al., 2007; Berardi et al., 2006; Shacked et al., 1999; 
Lasmèzas et al., 1997) and the recent finding of small RNAs possibly associated to the TSE 
infectious agent (Simoneau et al., 2009) is bringing to a renewed interest towards the viral 
hypothesis. 
A third hypothesis lays in the middle: the agent may be a particle called “virino” that is composed 
by an exogenous nucleic acid enveloped in the host prion protein (Dickinson et al., 1988). 
 
1.  4   TSE STRAINS 
After the seminal observation that scrapie disease gave rise to different clinical syndromes in 
experimentally affected goats (“scratching” and “drowsy” phenotypes) (Pattison and Millson, 
1961), it was only with the development of modern strain characterization techniques in the mouse 
model that the existence of multiple infectious prion “strains” or “isolates” was detailed and 
demonstrated beyond any doubt (Bruce et al., 1991).  
Different strains are traditionally distinguished on the basis of the incubation period, the 
neuropathological profile and the clinical signs in the recipient host (Bruce, 2003).  
Incubation period is defined as the time elapsed from the experimental inoculation to the 
development of clinical disease and for a given host-infectious strain combination it is a function of 
the infectious titre and the route of inoculation. For these reasons, although inoculation of different 
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prion strains in the same host usually results in different and reproducible incubation times, this 
parameter should be cautiously regarded (Bruce, 1993). A second feature that allows to distinguish 
the strains is the neuropathological profile or “lesion profile”, represented by the distribution and 
the degree of neurological damages found in the brain of infected animals, according to a 
standardized procedure for grading the severity of spongiform degeneration in nine brain areas 
(Fraser and Dickinson, 1973). More recently, some biochemical properties of the pathological prion 
protein have been added to the list of the traits that characterize prion strains, such as the 
electrophoretic mobility after PK digestion (Collinge et al., 1996; Parchi et al., 1996), extent of PK 
resistance (Bessen et al., 1992a), stability towards denaturing agents (e.g. guanidine HCl), position 
and intensities of infrared bands associated with β-sheet structures, and metal binding capacities 
(Thomzig et al., 2004; Safar et al., 2000, 1998; Kuczius and Grouschup, 1999; Wadsworth et al., 
1999). Moreover, an important factor contributing to the diversity among the strains is the PrP
TSE
 
glycosylation: the relative ratios of di-, mono-, and unglycosylated forms of the pathological protein 
differ in various prion strains (Khalilli-Shirazi et al., 2005) (figure 1. 5). 
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Figure 1. 5. Models of prion strains variation. Upon experimental inoculation of susceptible animals with identical 
genetic background, prion strains exhibit specific traits („phenotype‟) such as: (1) incubation time and 
attack rate, (2) PrP
TSE
 pattern in Western blot, (3) distribution of PrP
TSE
 deposits in the brain, (4) 
distribution and intensity of vacuolation in standardized brain areas („lesion profile‟) (modified from 
Béringue et al., 2008a). 
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In some cases these differences are so evident that are used in prion strain typing, as for example to 
discriminate between sCJD (type 2A) from vCJD (type 2B). Fourier transformed infrared 
spectroscopy (FTIR) (Aucouturier et al., 1999; Caughey et al., 1998) and conformation dependent 
immunoassay (Bellon et al., 2003; Safar et al., 1998) confirm the hypothesis that different 
structures acquired by PrP
TSE
 may account for prion strains differences. However, the molecular 
basis for the biochemical variety of PrP
TSE
 and how this relates to disease features remain 
unidentified. 
Among available experimental host species, the mouse model is widely used for TSE strain primary 
passage and characterization allowing to identify more than twenty phenotypically distinct strains 
from different sources: goat and sheep scrapie (Bruce et al., 1993), BSE from cattle (Bruce et al., 
2002; Lasmezas et al., 1996), sCJD and GSS from human sources (Muramoto et al., 1992; Tateishi 
et al., 1984; Manuelidis et al., 1978). Serial passages in the same species with constant biological 
conditions permit to stabilize and define a prion isolate (see next paragraph). 
On some occasions, the experimental passage into mice led to the isolation and separation of 
different infectious strains coexisting in a single natural host. A representative example is the 
isolation of “drowsy” (DY) and “hyper” (HY) strains after the injection of the agent responsible for 
transmissible mink encephalopathy (TME) in the Syrian hamsters (Bartz et al., 2000; Bessen et al., 
1992b). After serial passages (hamster-to-hamster) incubation periods became stable and could be 
assigned to two groups of different clinical signs: 150 days to the group that presented lethargy (so 
this strain was called “drowsy”) and 60 days to the group characterized by hyperactivity (the strain 
was then called “hyper”). Differences among the two groups were also concerning the vacuolation 
distribution and PrP
TSE
 deposition in different brain regions (Bessen et al., 1994), as well as 
electrophoretical mobility of the pathological isoform of the PrP (19 kDa for the unglycosylated 
band of DY, 21 kDa for that of HY) (Bessen et al., 1995). Furthermore, DY and HY had a different 
resistance to PK digestion, DY being more sensitive than HY (Bessen et al., 1992a).  
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1.  5   EXPERIMENTAL TRANSMISSION STUDIES AND THE SPECIES BARRIER 
Transmission of TSE disease from a species to another is often characterized by a prolonged 
incubation period and an incomplete attack rate (the number of animals affected) as compared with 
the intra-species transmission. This phenomenon is known as “species barrier” and in some cases 
can be abrogated through serial passages into the same host, after which a reduction of incubation 
time and a higher attack rate is observed, reflecting the adaptation, or rather, the selection of the 
most virulent strain from the original inoculum into the new species (Béringue et al., 2008a). Once 
stabilized into the new host, each strain can be serially propagated in vivo with high reproducible 
incubation period, clinical signs, lesion profile, and biochemical characteristics of PrP
TSE
, together 
giving the “strain signature” in that host species. 
Early studies suggested that the species barrier lies in the degree of homology of PrP amino acid 
sequence between the donor and the host species (Scott et al., 1989), as PrP sequence identity leads 
to an enhanced susceptibility to the disease and to a reduced incubation period. Consequently in the 
years a lot of different models of transgenic mice for sheep (Crozet et al., 2001; Vilotte et al., 2001; 
Westaway et al., 1994), bovine (Bèringue et al., 2006; Buschmann et al., 2005; Castilla et al., 2003; 
Scott et al., 1999) and human (Beringue et al., 2008b; Asano et al., 2006; Bishop et al., 2006; Korth 
et al., 2003; Taguchi et al., 2003; Asante et al., 2002; Kitamoto et al., 2002; Telling et al., 1994) 
were created with the purpose to break the barrier and facilitate transmission studies. Usually, 
transgenic mice with the same PrP primary structure as the donor species are more susceptible to 
the disease compared to the wild-type mice and can replicate some original strain properties, such 
as PrP
TSE
 molecular profile. 
On the other hand it is important to consider that PrP sequence diversity alone cannot explain the 
presence of species barrier. This aspect has been brought to the light by the capacity of the BSE 
agent to transmit to a large panel of different species (exotic ruminants, cats and humans) retaining 
some strain features such as the PrP
TSE
 molecular profile. Another representative example of 
transmission efficiency in absence of PrP sequence identity is the experimental transmission of 
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sporadic and genetic CJD isolates to bank voles (a newly discovered rodent model). Such human 
strains propagate in these rodents with a low or absent transmission barrier despite the wide 
divergence between human and vole PrP primary structure (Nonno et al., 2006). Moreover wild 
type mice are more susceptible to vCJD and BSE compared to human or bovine transgenic mice 
(Bishop et al., 2006). Actually a general opinion is that both PrP sequence and the strain properties 
contribute to the “species barrier” or, more correctly, to the “transmission barrier” (Scott et al., 
2005). 
 
1.  6   SPORADIC CJD  
The sporadic form of CJD (sCJD) accounts for 85% of the total human cases of TSEs with an 
incidence of 1-2 cases per million people per year worldwide, with an equal incidence in men and 
women aged between 60-70 years (Ladogana et al, 2005). The aetiology of sCJD is still 
unidentified, since the disease occurs in individuals that do not present mutations on PRNP gene, 
nor there is any evidence of accidental exposure of the patients to an infectious source. It has been 
speculated that the disease is the consequence of spontaneous conversion of PrP
C
 to PrP
TSE
 as a rare 
stochastic event (Wadsworth and Collinge, 2007), possibly facilitated by a hypothetical presence of 
somatic PRNP mutations which would explain the late onset of the disease. Alternatively, a change 
in the biochemical properties of the microenvironment surrounding the protein could be the trigger 
for PrP pathological conversion (Zanusso et al., 2001). 
Most cases of sCJD present at onset a rapidly progressive dementia with myoclonus. During the 
course of the disease the patient can develop extrapyramidal or pyramidal signs, visual or cerebellar 
disturbance and, at later stages, akinetic mutism. Other rarer forms of sCJD show different clinical 
presentations such as cerebellar ataxia rather than cognitive impairment (ataxic CJD, 10% of the 
total sCJD cases), persistent visual disturbances for several weeks before the appearance of other 
clinical signs (Heidenhain form of sCJD). In the majority of cases, the median duration of the 
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disease is around 3-6 months. A longer duration of 12 months is observed in 15% of cases, while in 
about 5% of patients the disease may last for more than 2 years.  
Different clinical phenotypes may be accompanied by specific neuropathological lesion profiles 
built on the basis of the severity and distribution of spongiosis, neuronal loss, gliosis, and PrP
TSE
 
deposition (Appleby et al., 2009). 
The vast majority of sporadic CJD patients can be categorized according to their genotype at the 
polymorphic codon 129 of PRNP gene and according to the electrophoretic mobility of the 
unglycosylated PK-resistant core of PrP
TSE
 (PrP
TSE
 type 1 and PrP
TSE
 type 2) (Parchi et al., 1999, 
1996). Unglycosylated PrP
TSE
 type 1 has a molecular size of about 21 kDa with an N-terminus 
corresponding to the main PK cleavage site at amino acidic residue 82, while unglycosylated PrP
TSE
 
type 2 has a molecular size of 19 kDa with an N-terminus at amino acidic residue 97 (figure 1. 6). 
The combination of the two parameters mentioned above allows to classify the sCJD cases in six 
main subgroups (MM1, MV1, VV1, MM2, MV2, VV2) corresponding to different clinical-
pathological phenotypes (table 1. 2).  
 
 
 
Figure 1. 6. PrPTSE types in sporadic CJD (modified from Gambetti et al., 2003). 
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Table 1. 2. Molecular and phenotypic features of the six subtypes of sCJD (modified from Parchi et al., 1999). 
 
sCJD 
subgroup 
% of 
Cases 
Onset 
(yr) 
Duration 
(mo) 
Clinical Features Neuropathological Features 
MM1 
MV1 
67 
3 
65.5 
62.1 
3.9 
4.9 
Rapidly progressive dementia, 
early and prominent 
myoclonus, typical EEG*; 
visual impairment or unilateral 
signs at onset in 40% of cases 
“Classic CJD” distribution of pathology; 
often prominent involvement of occipital 
cortex; “synaptic type” PrP staining; in 
addition, one-third of cases shows confluent 
vacuoles and perivacuolar PrP staining 
VV2 16 61.3 6.5 Ataxia at onset, late dementia, 
no typical EEG* in most cases 
Prominent involvement of subcortical, 
including brain stem nuclei; in neocortex, 
spongiosis is often limited to deep layers; 
PrP staining shows plaque-like, focal 
deposits, as well as prominent perineuronal 
staining 
MV2 9 59.4 17.1 
Ataxia in addition to 
progressive dementia, no 
typical EEG*, long duration (2 
yr) in some cases 
Similar to VV2 but with presence of 
amyloid-kuru plaques in the cerebellum, and 
more consistent plaque-like, focal PrP 
deposits 
MM2-
thalamic 
2 52.3 15.6 
Insomnia and psychomotor 
hyperactivity in most cases, in 
addition to ataxia and cognitive 
impairment, no typical EEG* 
Prominent atrophy of the thalamus and 
inferior olive with little pathology in other 
areas; spongiosis may be absent or focal, and 
PrP
TSE
 is detected in lower amount than in 
the other variants 
MM2-
cortical 
2 64.3 15.7 Progressive dementia, no 
typical EEG* 
Large confluent vacuoles with perivacuolar 
PrP staining in all cortical layers; cerebellum 
is relatively spared 
VV1 1 39.3 15.3 Progressive dementia, no 
typical EEG* 
Severe pathology in the cerebral cortex and 
striatum with sparing of brain stem nuclei 
and cerebellum; no large confluent vacuoles, 
and very faint synaptic PrP staining 
 
* Typical EEG: electroencephalogram showing periodic sharp-waves complexes typical of sCJD 
 
 
Polymorphism M/V at position 129 influences not only the susceptibility and the phenotypic 
features of the disease (Pocchiari et al., 2004), but also the production of PrP
TSE
 types: MM 
homozygosity is more frequently associated with type 1 PrP
TSE
, while VV or MV favour the 
production of PrP
TSE
 of type 2 (Parchi et al., 2000). From subsequent characterization studies of 
sCJD it was found that about 30% of cases accumulate both type 1 and type 2 in the brain, either in 
the same or in distinct anatomical areas (Notari et al., 2007; Polymenidou et al., 2005; Puoti et al., 
1999). 
As occurs with any other biological phenomenon, such a rigorous classification can not comprise 
the whole variability of clinical and pathological CJD phenotypes. However it remains a precious 
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tool to recognize atypical and rare forms of human TSEs that may represent emerging infectious 
strains with an unknown risk for humans. 
 
1.  7   sCJD TRANSMISSION AND TRANSGENIC HUMANIZED MICE 
Experimental transmission studies of human TSE diseases were first carried on non-human 
primates, such as chimpanzees, squirrel monkeys and cynomolgus macaques as they are 
evolutionary closer to humans than any other animal model and subsequently showed to have a 
similar PrP homology with the human counterpart (Williams et al., 2007; Herzog et al., 2005 
Brown et al., 1994). In spite of their reliability, these studies are expensive, time consuming and 
burdened with ethical concerns, and are currently used only to produce data that are urgently needed 
to face public health problems. 
Most types of sCJD did not transmit efficiently to wild-type laboratory mice (Nonno et al., 2006; 
Bruce et al., 1997), hence to overcome the human to mouse species barrier several lines of 
transgenic mice expressing the human prion protein have been developed (table1. 3). 
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Table 1. 3.  Transgenic lines expressing human PrP. 
 
Tg line 
(genotype) 
Transgenic 
method 
(GT/RGI
a
) 
Expression level
b
 Reference 
Tg152 (MM) RGI 4-8 Telling et al., 1995 
Tg110 (VV) RGI 1 Telling et al., 1994 
Tg440 (MM) RGI 2 Telling et al., 1995 
Tg650 (MM) RGI 6 Beringue et al., 2008b 
HuMM (MM) GT 1 Bishop et al., 2006 
HuVV (VV) GT 1 Bishop et al., 2006 
HuMV (MV) GT 1 Bishop et al., 2006 
Tg35 (MM) RGI 1-2 Asante et al., 2002 
Tg45 (MM) RGI 4 Asante et al., 2002 
Ki-Hu129M/M 
(MM) 
GT 1 Kitamoto et al., 2002 
Ki-Hu129M/V 
(MV) 
GT 1 Kitamoto et al., 2002 
Ki-Hu129V/V 
(VV) 
GT 1 Kitamoto et al., 2002 
 
a) GT: gene targeting; RGI: random genomic insertion  
b) compared to PrP expression in the original host species 
 
 
 
Most of such humanized transgenic lines were engineered on endogenous PrP null background in 
order to avoid any interfering effect of the resident murine PrP gene. Transgenic mice have 
contributed enormously to the abrogation of the species barrier creating new valuable models 
characterized by short incubation periods and high attack rates in transmission experiments, 
therefore allowing a better investigation of the molecular basis of human prion strains (Grouschup 
and Buschmann, 2008; Telling, 2008). The insertion of human PRNP gene in the murine genome 
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was performed by two different techniques. The random genomic insertion (RGI), is based on the 
microinjection of the DNA of interest into a fertilized mouse oocyte; this means that it is neither 
possible to control the insertion site nor to control the number of copies of the transgene integrated, 
thus leading to an overexpression of the human PrP in the murine background. Furthermore, the 
number of copies integrated is not directly proportional to the expression levels of PrP, thus 
highlighting the effects that the point of insertion may have on the expression of the newly 
integrated transgene. These models of transgenic mice may be useful to investigate the effect of PrP 
expression levels on the susceptibility to the disease and may represent a valuable resource as a 
rapid mouse bioassay mode (some of the lines developed clinical signs in less than 100 days post-
inoculation) but they cannot model the natural pathogenesis of TSEs. 
As a further drawback it is not possible a comparison between different mouse lines since any of it 
has different level of PrP expression. 
The alternative gene targeting technique (GT) (Manson and Tuzi, 2001), is based on the 
homologous recombination and allows to replace the murine prnp gene with the corresponding gene 
derived from another species. In the case of humanized mice the human PRNP is present in a single 
copy in the same site where was located the prnp, therefore under the natural expression modifiers 
that determine physiological expression levels of the human PrP (Bishop et al., 2006). Moreover 
this system allows a direct comparison between the different mouse lines. The transgenic mice used 
to perform the studies described in this thesis, produced by means of GT technique, express the 
human PRNP with three alternative genotype at the polymorphic codon 129 (MM, MV, VV), the 
most recognised factor of susceptibility and pathological phenotype in sCJD. 
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2. AIM OF THE STUDY 
Sporadic CJD, the most common form of human TSE diseases, presents distinctive phenotypes, that 
could be discriminated by clinical signs at onset, duration of disease, type and distribution of 
neuropathological lesions (spongiosis, gliosis, and neuronal loss), and by the type and the pattern of 
deposition of the pathological prion protein PrP
TSE
, an hallmark of TSE diseases. Parchi and 
collaborators (Parchi et al., 1996) have shown that the polymorphic codon 129 of the PRNP gene 
and the PrP
TSE
 type (1 or 2) that accumulates in the patient‟s brain are the major determinants of 
disease phenotype. Thus, they classified all cases of sCJD into six subtypes (MM1, MM2, VV1, 
VV2, MV1, and MV2). 
Transmission studies of the six sCJD subtypes into transgenic mice expressing the human prion 
protein suggested that partly the variety of the clinical-pathological phenotypes of sCJD might be 
related to the presence of distinct human strains of prion agent. 
There are, however, rare cases of sCJD that do not fulfils any of the above criteria, suggesting that 
other minor infectious strains might be responsible of these rare variants. It is still controversial 
whether TSE strains are influenced by yet unknown endogenous or exogenous factors, but the 
understanding of the biological characteristics of these strains will improve our knowledge of the 
pathogenesis of the disease, and hopefully, to find an appropriate therapy for these otherwise fatal 
disorders. 
Aim of my PhD work was to determine whether in 3 atypical Italian sCJD cases identified through 
the national surveillance of CJD and related disorders at the Istituto Superiore di Sanità, Rome, it 
was possible to identify novel human prion strains. This objective was pursued by inoculating brain 
extracts of each patient into gene-targeted transgenic mice carrying the human PRNP gene with the 
three possible genotypes (MM or VV or MV) at the polymorphic codon 129. Survival times, attack 
rates, lesion profiles, and molecular analysis of the PrP
TSE
 type recovered from mice brains for each 
genotype/inoculum combination will be compared with data from the transmission of the “classical” 
sCJD subtypes to clarify the basis of these atypical cases. 
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3. METHODS 
3.  1   ANIMALS 
3.  1.1   Transgenic mice 
The transgenic model (HuTg) used in transmission experiments is represented by three transgenic 
lines expressing human PrP homozygous for methionine (HuMM), valine (HuVV) or heterozygous 
(HuMV) at the polymorphic position 129 in a 129/Ola background (Bishop et al., 2006). The 
murine prnp gene was entirely replaced by human PRNP gene by using gene targeting technique 
(Bishop et al., 2006; Manson and Tuzi, 2001) that allows the production of human PrP in the same 
tissues and at the same levels as that wild-type PrP. The three transgenic lines have identical 
genotype, except for the polymorphic codon 129. Thus the differences in the transmission 
properties can be directly attributable to the codon 129. 
Initial breeding stocks (HuMM and HuVV mice), kindly supplied by Prof. Jean Manson (The 
Roslin Institute, Neuropathogenesis Division, University of Edinburgh), were used to establish 
successful colonies of human transgenic mice. The heterozygous HuMV line was generated by 
crossing the two homozygous lines. The experimental breeding procedures were carried in the 
animal facility of the Department of Cell Biology and Neuroscience - Istituto Superiore di Sanità, 
Roma in collaboration with qualified and authorized staff. 
 
3.  1.2   Confirmation of the genotype of the transgenic mice 
The following method was used to check both the genotype of the original breeding stocks and that 
of the mice used for the transmission experiments. 
Genomic DNA was isolated from the mouse tail following standard laboratory procedures. Briefly, 
tailsnips were cut and incubated overnight at 53°C in 0.5 ml of tail solution (50mM Tris-HCl, pH 8, 
100mM EDTA, 1% SDS, 100mM NaCl) supplemented with 500 g of Proteinase K (PCR grade, 
Roche). DNA was extracted using phenol/chloroform, precipitated in isopropanol and dissolved in 
TE buffer (10mM Tris-HCl, pH 7.5, 1mM EDTA) and stored at -20°C until use. 
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DNA was amplified for mouse prnp orf with primers Mouse PrpF and R (figure 3.1) to verify the 
absence of endogenous gene. Positive and negative controls were included. 
PCR was done using 200-500 ng of DNA in 50 l volume with standard buffers (Taq PCR Master 
Mix kit, Qiagen ). PCR was run through 40 cycles at 94°C for 30 seconds, at 58°C for 30 seconds, 
at 72°C for 30 seconds. PCR products were run on 1.5% agarose gel and visualized by ethidium 
bromide under UV light. 
Transgene integration in mice was analyzed by PCR using human primers for PRNP (figure 3. 1) 
and the polymorphism at codon 129 was detected by direct sequencing of PCR products. PCR was 
done using 200-500 ng of DNA in 50 l volume with standard buffers (Taq PCR Master Mix kit, 
Qiagen). The first step was 95°C for 15 minutes, continued by 40 cycles of 94°C for 40 sec, 62°C 
for 40 sec, and 72°C for 40 sec and the final elongation step at 72°C for 10 minutes. The PCR 
positive products were run on 1.5% agarose gel, visualized by ethidium bromide under UV light 
and isolated using a QIAquick PCR Purification kit (QIAGEN) according to the standard protocol 
provided by QIAGEN. The purified PCR products were sequenced by the Sanger 
dideoxynucleotide chain termination method (Slatko et al., 2001) with the GenomeLab DTCS-
Quick Start Kit (Beckman). Sequences were run for 25 cycles at 96°C for 30 minutes, 56°C for 15 
minutes, and 60°C for 4 minutes. Purified sequences were then electrophoresed on the Beckmann 
Coulter CEQ 8000 capillary sequencer and analyzed using the sequence navigator software 
provided by the manufacturer. All PCR and sequencing cycles were performed using the Gene Amp 
PCR system 9700 (Perkin Elmer). All tests were performed in duplicate. 
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Figure  3. 1 
 
 
Human sequence of the construct inserted in the mouse gene: 
 
ATG GCG AAC CTT GGC TAC TGG CTG CTG GCC CTC TTT GTG ACT ATG TGG 
ACT GAT GTC GGC CTC TGC AAA AAG CGG CCA AAG CCT GGA GGG TGG AAC 
ACC GGT GGA AGC CGG TAT CCC ggg cag ggc agc cct gga ggc aac cgc tac 
cca cct cag ggc ggt ggt ggc tgg ggg cag cct cat ggt ggt ggc tgg 
ggg cag cct cat ggt ggt ggc tgg ggg cag ccc cat ggt ggt ggc tgg 
gga cag cct cat ggt ggt ggc tgg ggt caa gga ggt ggc acc cac agt 
cag tgg aac aag ccg agt aag cca aaa acc aac atg aag cac atg gct 
ggt gct gca gca gct ggg gca gtg gtg ggg ggc ctt ggc ggc tac 
(G/A)tg ctg gga agt gcc atg agc agg ccc atc ata cat ttc ggc agt 
gac tat gag gac cgt tac tat cgt gaa aac atg cac cgt tac ccc aac 
caa gtg tac tac agg ccc atg gat gag tac agc aac cag aac aac ttt 
gtg cac gac tgc gtc aat atc aca atc aag cag cac acg gtc acc aca 
acc acc aag ggg gag aac ttc acc gag acc gac gtt aag atg atg gag cgc 
gtg gtt gag cag atg tgt atc acc cag tac gag agg gaa tct cag gcc tat 
tac cag aga gga tcg agc atg gtc ctc ttc tcc tct cca cct gtg atc 
ctc ctg atc tct ttc ctc atc ttc ctg ata gtg gga tga ggaaggCCT 
 
 
Bold: primers for human PRNP screening by PCR 
CAPITALS: mouse sequence 
Lower case: human sequence 
Blue case: M129V polymorphism 
Red case: primers used for PCR products sequencing 
 
 
 
Primers used for PCR and sequencing: 
 
Hum F1 5’-gca gcc ctg gag gca acc gc-3’ 
Hum R1 5’-aac cac gcg ctc cat cat ctt-3’ 
 
Hum F 5’-cta ccc acc tca ggg cgg tgg tgg c-3’ 
Hum R 5’-tgg ttg ctg tac tca tcc at-3’  
 
MousePrpF 5’ tgt ggc agg ggc tgc g-3’ 
MousePrpR 5’-gct gga tct tct ccc g-3’ 
 
 
Bold: primers for human PRNP screening by PCR 
Red case: primers used for PCR products sequencing. 
Green case: primers used for mouse prnp PCR. 
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3.  2   INOCULATION OF THE TRANSGENIC MICE  
3.  2.1   Sporadic CJD patients 
Patients were recruited through the National CJD surveillance unit of the Istituto Superiore di 
Sanità, that received the permission from the ethical committee to collect tissue samples from 
patients referred to the unit and use them for research purposes. Patient CJD diagnoses were 
confirmed by histopathology, immunohistochemistry and Western blot (Cardone et al., 1999). Each 
of the three transgenic mice lines were inoculated with the sCJD cases described below: 
 A typical CJD case (referred in the thesis as MM1), characterized by a onset at 71 years old 
and a duration of 4 months. The patient had a pseudoperiodic EEG, typical for sporadic 
CJD, and manifested dementia, myoclonus and pyramidal, extrapyramidal, cerebellar and 
visual signs. After the death the brain was removed and half hemisphere was fixed in 
formaline for the histological investigations and the other half was frozen to perform 
biochemical, genetic and transmission studies. The brain presented intense spongiosis. 
Western blot analysis revealed presence of type 1 PrP
TSE
. Genetic analysis on PRNP 
displayed methionine homozygosity at polymorphic codon 129 and no presence of disease-
associated mutations. The present case was used as control, because of it is the most 
common form of sporadic CJD. 
 An atypical case (referred in the thesis as MVx) (Zanusso et al., 2007), represented by a 
patient who exhibited behavioural and personality changes followed by rapidly evolving 
dementia. The duration was of 14 months. After the death the brain was removed and half 
hemisphere was fixed in formaline for the histological investigations and the other half was 
frozen to perform biochemical, genetic and transmission studies. Post-mortem 
neuropathological examination of the brain showed an atypical CJD phenotype 
characterized by intracellular prion protein deposition and the presence of axonal swellings 
filled with amyloid fibrils. Biochemical analysis of the pathological prion protein disclosed 
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a previously unrecognized PrP
TSE
 tertiary structure lacking diglycosylated species. PRNP 
analysis revealed Met/Val heterozigosity at codon 129 and no pathological mutation.  
 A case (referred in the thesis as MV1/2) defined atypical because characterized by an early 
onset (38 years old), a long duration (36 months), psychiatric symptoms and sleep 
disturbances. After the death the brain was removed and half hemisphere was fixed in 
formaline for the histological investigations and the other half was frozen to perform 
biochemical, genetic and transmission studies. Neuropathological studies showed diffuse 
spongiosis and kuru-like plaques. Biochemical analysis of the pathological prion protein in 
the brain revealed the presence of both PrP
TSE
 types (type 1 and type 2). The part of the 
brain that was inoculated for transmission studies in the transgenic mice contains only type 2 
PrP
TSE
, in order to avoid having a confounding factor in the inoculum (co-presence of type 1 
and type 2). Genetic investigation on PRNP showed Met/Val heterozigosity at codon 129 
and no disease-linked mutations. 
 An atypical case (referred in the thesis as MV2At) characterized by an early onset (44 years 
old), a very long duration (62 months) and psychiatric symptoms. After death, the brain was 
removed and half hemisphere was fixed in formaline for the histological investigations and 
the other half was frozen to perform biochemical, genetic and transmission studies. 
Neuropathological analysis showed a diffuse spongiosis and deposition of kuru-plaques like 
in the cerebellum and Western blot displayed type 2 PrP
TSE
. Sequencing of PRNP gene 
revealed Met/Val heterozygosity at codon 129 and no pathological mutations. 
 
3.  2.2   Preparation of inocula from human brains 
Human brain samples were collected from areas showing pathology and PrP
TSE
 accumulation. Brain 
tissues were homogenized at 10% (w/v) concentration in sterile phosphate buffered saline (PBS) 
(138 mM NaCl, 2.7 mM KCl, 8 mM Na2HPO4, KH2PO4 1.4 mM, pH 7.6) using new, dedicated 
glass/Teflon Potter tissue grinders. The 10% homogenate was aliquoted into 5 ml glass vials, 
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sealed, and stored at -80ºC (Pocchiari et al., 1989). On the day of inoculation the homogenate was 
thawed, vortexed to homogeneity and then diluted to 1% (w/v) in sterile PBS. Preparation and 
dilution of inocula were carried out in a Class 2 microbiological Safety Cabinet, located in a 
Category 3 hazard risk room. 
 
3.  2.3   Inoculation of mice 
The animals were housed in compliance with Directive N. 86/609/EEC on the protection of animals 
used for experimental and other scientific purposes and the Legislative Decree of 27 January, N. 
116/12 (Gazzetta Ufficiale-Suppl. Ord.- n. 40, 18 febbraio 1992). Before the inoculation procedure, 
mice were anesthetized by intraperitoneal administration of 0.1 ml of a solution prepared by mixing 
1 ml Ketamine-50, 0.15 ml Xylazine, 9.75 ml of saline (NaCl 0.9%). The inoculum (20 µl of 1% 
human brain homogenate) was injected into the left cerebral hemisphere by using an insulin syringe 
with a 26G needle. The animals were sacrificed by CO2 asphyxia. Experimental inoculation 
procedures were carried out in the animal facility of the Department of Cell Biology and 
Neuroscience - Istituto Superiore di Sanità, Roma in collaboration with qualified and authorized 
staff. 
 
3.  3   EXAMINATION OF INOCULATED MICE 
3.  3.1   Clinical signs 
The animals were observed two days per week from 100 days after the inoculation to record the 
onset of the clinical signs which manifest as motor dysfunctions (ataxia), rigidity of the tail, 
hunched back and weight loss (Carp et al., 1984) and were culled at the terminal stage of the 
disease. 
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3.  3.2   Survival time 
For each combination inoculum/genotype we recorded the survival time, corresponding to the time 
between the inoculation and the culling, for animals clinically sick, or to the time intercurrent 
between inoculation and spontaneous death, for animals that did not show clinical signs. 
Survival time of each group of animals is expressed as the average of the survival times of PrP
TSE
 
positive mice only. The survival curves were built according Kaplain-Meier method by considering 
PrP
TSE
 positivity. All PrP
TSE
 negative cases entered in the analyses as censored. Comparison 
between survival curves were carried out by the log-rank test. 
 
3.  3.3   Histological and immunohistochemical examination 
At postmortem, each brain was divided in two parts by a sagittal paramedian cut. One half was 
immediately frozen and stored at -80°C for Western blot analysis, while the other half was 
immersed and fixed in 4% buffered formaldehyde for neuropathological analyses. 
Fixed brains were cut in five sections (2 mm thick) at standard coronal levels, transferred into 
embedding cassettes, immersed in 98% formic acid for 1 hour to reduce infectivity and washed for 
2 hours in running water. The samples were then dehydrated in graded alcohols (70% o.n. - 95% 
o.n. - 100% for 2 h), clarified in xylene for 30 min and finally embedded in paraffin wax. 
Five-µm-thick sections were cut on rotative microtome, collected on glass slides for histological 
analyses or on charged slides (Superfrost® Plus slides, Menzel-Glaser) for immunohistochemistry 
and let dry at 37°C overnight in an oven.  
For histology, the slides were dewaxed in xylene (2 x 20 mins), rehydrated in decreasing graded 
alcohols (100% 2 x 20min, 95% - 70% - distilled water 5 min each), stained with haematoxylin and 
eosin (H&E), coded and examined blind with a Leica microscope for pathological assessment. 
For the construction of the lesion profile, vacuolar changes were scored (table 3. 1) in nine grey-
matter areas of the brain (table 3. 2) according to the scoring system introduced by Fraser and 
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Dickinson (Fraser and Dickinson, 1968). Vacuolation scores are derived from at least four 
individual mice per group, and are reported as means ± standard error of the mean.  
 
 
 
Table 3. 1.  Definition of vacuolation scores. 
 
Vacuolation score Description 
0 No vacuoles 
1 A few vacuoles widely and unevenly scattered 
2 A few vacuoles evenly scattered 
3 Moderate numbers of vacuoles, evenly scattered 
4 Many vacuoles with some confluence 
5 
Dense vacuolation with most of microscopic field confluent, 
lace-like appearance 
 
 
Table 3. 2.  List of the brain regions of HuTg mice and corresponding numbers used to build up  
                                       the “lesion profile” curves. 
 
 
Brain regions 
Corresponding numbers in the lesion 
profile figures 
Dorsal medulla 1 
Cerebellar cortex 2 
Superior colliculus 3 
Hypothalamus 4 
Thalamus 5 
Hippocampus 6 
Septum 7 
Posterior cerebral cortex 8 
Anterior cerebral cortex 9 
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For immunohistochemistry, slides were dewaxed, rehydrated and immunostained for the presence 
of PrP
TSE
 using the mouse monoclonal antibody (mAb) SAF84 (SPI-BIO, Massy, France). The 
sections were immersed for 10 min in methanol containing 3% H2O2 to block endogenous 
peroxidase activity, washed in distilled water for 10 min and subjected to antigen retrieval by 
autoclaving at 121°C for 30 minutes in distilled water. The slides were cooled at room temperature, 
treated with 98% formic acid for 1 min to enhance staining, rinsed, and incubated with 4 M 
guanidine thiocyanate for 30 min at 4°C in a humid camber. After a one hour incubation in PBS 
containing 3% Normal Goat Serum (NGS), the slides were then incubated overnight at 4C with 
mouse mAb SAF84 (1.5 g/ml) in PBS/NGS 3%. Subsequent antibody detection involved 
incubation with a biotinylated goat anti mouse secondary antibody for one hour (1:200 dilution, 
Vector Laboratories) at room temperature, followed by incubation with the avidin-biotin-peroxidase 
complex (Vectastain ABC-Elite kit, Vector Laboratories) according to the manufacturer‟s 
instructions. The samples were stained with 3‟- 3‟diaminobenzidine (DAB, Sigma) or 3-amino-9-
ethylcarbazole substrate (AEC Plus; Dako, Glostrup, Denmark) as chromogen to visualize the 
reaction product and then counterstained with hematoxylin. Positive (sections of previously 
immunostained brains) and negative (sections stained with the omission of the primary antibody 
from the incubation solution and sections from uninfected brains) control sections were included in 
each run. 
 
3.  3.4   Preparation of the brain tissue for the Western blot analysis  
The protocol described below was kindly provided by Doctor Matthew Bishop (National CJD 
Surveillance Unit, Western General Hospital, Edinburgh). 
Each frozen half brain was thawed, transferred in a 2 ml safelock sterile tube and weighed. A 
homogenate of the tissue was prepared to a final concentration of 10% (w/v) in sterile saline (NaCl 
0.9%) by using a disposable plastic micropestle. An aliquot of 250 µl of the 10% homogenate was 
transferred to a 1.5 ml safelock tube and 25 µl of extraction buffer (5% Nonidet P-40, 5% Sodium 
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deoxycholate, 200 mM Tris-HCl pH 7.4) were added. After mixing by vortex, the sample was 
centrifuged at 2000 rpm for 5 minutes at 4 ºC in a microfuge. 
An aliquot of 100 µl of supernatant was taken and treated with proteinase K (PK, Sigma) to a final 
concentration of 50 µg/ml. This step enables to detect only the pathological form and not the 
cellular form of PrP (completely digested after this treatment). The digestion was carried out at 
37ºC for 1 hour with constant agitation (1000 rpm of Thermomixer), then was stopped by adding 2 
µl of 25 X Complete Inhibitors Cocktail (Roche). 
The samples were centrifuged at 14000 rpm for 60 minutes at 4 ºC in a microfuge. The resulting 
pellet was resuspended in 20 µl of LDS Sample buffer 2X prepared from NuPAGE LDS Sample 
buffer 4 X Invitrogen (106 mM Tris-HCl, 141 mM Tris base, 2% LDS, 10% glycerol, 0.51 mM 
EDTA, 0.22 mM Serva Blue G250, 0.175 mM Phenol red) plus DTT 0.5 M, boiled at 99 ºC for 10 
minutes and stored at – 20 ºC. 
Tissue manipulation was carried out in a Class 2 microbiological Safety Cabinet in a Category 3 
hazard risk room. 
 
3.  3.5   PrP
TSE
 detection by Immunoblot 
Denatured samples were loaded onto a 1 mm thick NuPAGE SDS Electrophoresis polyacrylamide 
gel (pH 7.0) with an acrylamide concentration of 12% (Invitrogen) and run for 2 h at 100 V 
constant voltage. 
Once proteins were separated, they were electrotransferred onto a nitrocellulose membrane by a 
semi-dry cell (Semi-dry transfer unit, Hoefer Semi-phore) in transfer buffer (25 mM Tris-base, 192 
mM Glycine, 20% methanol) for 1 hour at constant amperage of 125 mA. The membrane was then 
incubated for 1 hour at 37 °C in blocking buffer: 5% milk powder (Non-Fat Dry Milk, Bio Rad) 
diluted in TBS / 0.05% Tween-20 (TBST) with constant agitation. This step is necessary to cover 
non-specific binding sites on the membrane. 
 34 
After two quick washes in TBST, the membrane was incubated with the anti-PrP 3F4 primary 
antibody diluted 1:1000 in 5% milk / TBST for overnight at 4°C with constant agitation. 3F4 
monoclonal antibody binds residues 109-112 of PrP (Lund et al., 2007; Kanyo et al., 1999; Bolton 
et al., 1991; Rogers et al., 1991) and was chosen for its high specificity and affinity for the human 
PrP (Kascsak et al., 1987). After 5 washes of 5 minutes each in TBST, the membrane was incubated 
for 2 hours at 37°C with constant agitation with anti-mouse IgG peroxidase-linked secondary 
antibody (Amersham) diluted 1:5000 in 5% milk / TBST. PrP bands were finally revealed by 
incubation for 1 minute in the dark with a solution containing luminol (Western Blotting Luminol 
Reagent, Santa Cruz Biotechnology) and exposure of the membrane to light sensitive film 
(Amersham Hyperfilm). 
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4. RESULTS 
4.  1   ATTACK RATE 
The presence of spongiosis in H&E stained brain sections or the detection of the pathological form 
of PrP (PrP
TSE
) in the brain (by immunohistochemistry or Western blot) were the essential 
parameters to define the transmission of the disease. The attack rates (percentage of diseased brains) 
for each combination inoculum/genotype are summarized in table 4. 1. 
MM1, MV1/2 and MV2At transmitted efficiently to all three lines with high percentages of attack 
rate. MV2At displayed the highest efficiency, with an attack rate of 100% in all three lines. 
MVx case transmitted only to HuVV mice with a low attack rate value. 
 
Table.  4. 1.  Attack rate.  
Inoculum from human 
sporadic CJD 
Mouse genotype PrP
TSE 
positive/tested Attack rate (% positive) 
MM1 
MM 18/19 95% 
VV 12/15 80% 
MV 18/18 100% 
    
MVx 
 
MM 0/14 0% 
VV 4/18 22% 
MV 0/14 0% 
    
MV1/2 
MM 13/16 81% 
VV 20/20 100% 
MV 17/19 89% 
    
MV2At 
MM 16/16 100% 
VV 20/20 100% 
MV 17/17 100% 
Italic red, clinical but not PrP
TSE
 positive.  
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4.  2   SURVIVAL TIME 
Transgenic mice inoculated with brain homogenates of sporadic CJD patients were difficult to 
evaluate for the onset of clinical signs because these were rather not specific, (i.e., hunching of the 
back, hypo-activity, lowering of the hind back, and ruffled fur), therefore, we regarded the time 
between inoculation and death as a more reliable end-point. The mean survival times for each 
inoculum/genotype combination are summarized in figure 4. 1 and in table 4. 2. 
 
Figure  4. 1.  Survival times of HuTg mice injected with different sporadic CJD cases. 
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 (grouped according to HuTg line)
0
50
100
150
200
250
300
350
400
450
500
550
600
650
700
HuMM HuVV HuMV
sCJD MM1
sCJD MV1/2
sCJD MV2At
sCJD MVx
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
B 
 
Survival times of HuTg inoculated with sCJD
 (grouped by inoculum type)
0
50
100
150
200
250
300
350
400
450
500
550
600
650
700
sCJD MM1 sCJD MV1/2 sCJD MV2At
HuMM
HuVV
HuMV
B 
 37 
Table  4. 2.  Survival times in days (mean ± SD) for each combination inoculum/genotype. 
 TRANSGENIC LINES 
sCJD INOCULUM HuMM HuVV HuMV 
MM1 402.7 ± 99.33 453.0 ± 112.6 415.1 ± 86.2 
MV1/2 510.2 ± 62.2 258.1 ± 21.1 540.8 ± 98.7 
MV2At 501.9 ± 88.2 229.1 ± 17.6 519.0 ± 100.8 
MVx 511.9 ± 106.9
#
 626.0 ± 28.6 453.6 ± 144.4
#
 
# 
Survival times of clinical positive but PrP
TSE
 negative mice (no PrP
TSE
 positive mice found) 
 
 
The Kaplan-Meier survival curves drawn for each inoculum are in figure 4. 2, showing the survival 
differences between the 129 genotypes. 
MM1 case successfully transmitted to the three lines with similar survival times and overlapping 
survival curves. Indeed no statistically significant differences among survival curves are present 
between different HuTg mice (p=0.13). 
MVx case transmitted only to HuVV mice with very long survival times. No survival data in the 
other different lines are available for comparison. 
MV1/2 successfully transmitted to all three HuTg lines, with significantly shorter survival times in 
HuVV as compared with HuMM and HuMV. In line with this observation, the survival curve for 
HuVV mice shows a very steep decay and is significantly different (p= 0.00) from those of HuMM 
and HuMV mice, which result statistically indistinguishable. 
MV2At transmission gave the same results as the MV1/2 inoculum in the three HuTg mouse lines 
with shorter survival time in the HuVV line with respect to HuMM and HuMV lines. Statistical 
analyses show a significantly (p= 0.00) shift of HuVV survival curve with regard to those of 
HuMM and HuMV, which do not differ between them.
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Figure  4.  2.  Kaplan-Meier survival curves grouped by inoculum type. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The Kaplan-Meier survival curves of each HuTg line inoculated with different inocula are depicted 
in figure 4. 3. These curves allow to visualize the effect of the inoculum type in the same 129 
genotype: in the HuMM line and HuMV line, the MM1 inoculum was faster than the MV1/2 and 
MV2At inocula whereas in the HuVV line, an opposite trend was observed with a relatively fast 
transmission in animals injected with MV1/2 and MV2At inocula, followed by MM1 and MVx 
which showed a very long survival time. 
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Figure  4. 3.  Kaplan-Meier survival curves grouped by HuTg mouse line. 
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4.  3   TOPOGRAPHY OF SPONGIOSIS AND PrP
TSE
 DEPOSITION 
To characterize the phenotype of affected mice, we analyzed the pattern of vacuolar degeneration in 
nine grey matter brain areas, which are represented by the lesion profile (figure 4. 4).  
The MM1 case presented a pattern of spongiosis that resulted remarkably similar among the three 
human transgenic lines, with slightly more intense spongiform changes in HuMV mice in all the 
areas, except in the superior colliculus (area 3). 
MV1/2 showed similar profiles of spongiform degeneration in HuMV and HuVV mice, with more 
severe changes in HuVV mice, confirming that this transgenic genotype is more susceptible to this 
inoculum. In HuMM mice the thalamus (area 5) was the area mainly affected similarly to HuMV 
mice, the other line with methionine (in heterozigosity) at codon 129.  
MV2At case produced more intense spongiform changes in HuVV and HuMM involving all brain 
areas except the cerebellar cortex (area 2). A much lower degree of spongiosis could be appreciated 
in HuMV were the thalamus (area 5) was the most severely affected area similarly to what observed 
in HuMM mice, the other methionine 129 containing genotype. 
While both the MV1/2 and the MV2At sCJD cases associated with vacuolation in the deep layer of 
the cerebral cortices, the MM1 determined vacuolation of superficial cortical layers in all infected 
animals (fig. 4. 5). 
In most of the animals belonging to the three genotypes, large vacuoles can be observed in several 
white matter areas (i.e. striatum, internal capsule, cerebellar white matter and medulla). The same 
vacuolation is however present in age-matched control animals, suggesting that such phenomenon 
may not be related to the disease but rather to an aging process (fig. 4. 6). 
All mice belonging to the three lines were negative at the neurophatological analysis both for the 
presence of spongiosis and for PrP
TSE
 deposition once inoculated with the MVx case. 
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Figure 4. 4.  Lesion profiles grouped by inoculum type. 
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Figure 4. 5. Vacuolation in the cerebral cortex of HuMM mice infected with MM1 sCJD (a,b) and with MV2At sCJD 
(c,d). Vacuoles are present in the superficial layers of the cortex in mice infected with MM1 sCJD (arrows in b) and in 
the deep layers of the cortex adjacent to the corpus callosum in mice infected with MV2At sCJD (arrows in d). b and d  
are higher magnifications of the boxed areas in a and c. CC: Corpus Callosum. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. 6. White matter vacuolation in affected (a) and healthy (b) animals in cerebellar cortex (arrows) and in 
vestibular nuclei (arrowheads). 
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When neuropathological data are analysed on the basis of the recipient genotype (figure 4. 7) it can 
be seen that in HuMM mice the three inocula determined different lesion profiles, highlighting the 
role of the strain on lesion distribution in the brain, despite the same 129 polymorphism in the host. 
Both MV cases (MV1/2 and MV2At) mainly targeted the thalamus (area 5), with the MV2At 
inoculum inducing a higher severity of the lesions in the hippocampus (area 6) and cerebral cortices 
(areas 8 and 9). HuMM mice infected with the MM1 sCJD case had a completely distinct lesions 
profile, characterized by a more severe vacuolation in the superior colliculus (area 3) and the 
septum (area 7), and a lower spongiform change in the thalamus (area 5). 
In HuVV mice, the two MV cases (MV1/2 and MV2At) produced an identical pattern of vacuolar 
changes, with the higher spongiform change in the thalamus (area 5), hippocampus (area 6) and 
cerebral cortices (8 and 9 areas). This pattern was clearly different from that observed with the 
MM1 sCJD case, where the level of vacuolation was less severe in all the nine areas except for the 
superior colliculus (area 3) and the septum (area 7). 
In HuMV mice, the MV1/2 and the MV2At sCJD cases had similar vacuolation scores in the 
posterior and central areas of the brain but lower severity of lesions in the hippocampus (area 6), 
septum (area 7) and cerebral cortices (areas 8 and 9) of animals injected with the MV2At sCJD 
inoculum. Again, mice injected with MM1 sCJD showed a completely different lesion profile 
characterized by the presence of lesions in all the nine areas examined. 
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Figure 4. 7.  Lesion profiles grouped by HuTg line. 
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Immunohistochemical analyses revealed a heterogeneous deposition of PrP
TSE
 in different brain 
areas with all three CJD subtypes (table 4. 3). After inoculation of MM1 case in HuMM mice, 
granular deposition can be observed in the ventral thalamic nuclei and only rare and small plaque-
like aggregates are present in the hippocampus. Scattered PrP
TSE
 deposits were also found in the 
septum and in the mesencephalic nuclei in some of the animals analyzed. 
In HuVV mice, the MM1 inoculum is characterized by the total absence of plaques and by the 
presence of little granular PrP
TSE
 deposition in the hippocampus; the thalamic nuclei are involved 
with few scattered deposits.  
In HuMV mice the thalamic nuclear group and the hippocampus are always sites of PrP
TSE
 
deposition, with the other brain areas involved only occasionally at the diencephalic (cortical) and 
mesencephalic level. Plaques are always absents. Animals with longer survival times are 
characterized by a more abundant PrP
TSE
 deposition. 
The MV1/2 case determined in HuMM mice granular PrP
TSE
 deposition in the thalamic nuclei, 
invariably present in all the animals analyzed; a variable number of plaques are observed along the 
corpus callosum at the level of the hippocampus and in few mice in the retrosplenial cortex but are 
absent in all other levels. Some granular deposits can be observed in the mesencephalon and in the 
medulla. As in HuMM mice, the MV1/2 inoculum in HuVV mice is characterized by a granular 
deposition in the thalamic nuclei and plaques along the corpus callosum. In some animals the 
PrP
TSE
 is also found in the motor cortex, in the mesencephalon and in the medulla.  
The ventral thalamus is the only area of deposition in HuMV mice inoculated with MV1/2, but in 
such mice the deposition is mainly represented by plaques whereas the granular deposition is almost 
absent.  
Regarding MV2At case in all the three mice lines, the pattern of PrP deposition is the same as for 
the MV1/2 inoculum, with granular deposits in the thalamus and plaques along the corpus callosum 
in HuMM and HuVV mice; and plaques, mainly present in the thalamus, in HuMV mice. 
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All three inocula (MM1, MV1/2, MV2At) determined in mice the presence of PrP
TSE
 deposition in 
the ventral nuclear groups of the thalamus (median and lateral nuclei, fig. 4. 8) and, interestingly, in 
the lateral nuclei, the PrP
TSE
 deposition parallels the distribution of the vacuoles.  
PrP plaques can be observed along the corpus callosum or in the thalamus in all three mice lines 
infected with the MV1/2 and MV2At inocula, and can be also easily identified with the 
haematoxylin and eosin staining (fig. 4. 9). Small plaque-like aggregates can be occasionally found 
in the hippocampus of MM mice infected with the MM1 sCJD. 
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Table 4. 3. PrP
TSE
 distribution and deposition pattern. 
Inoculum  Mouse genotype  Brain level / PrP
TSE
 pattern  
    A  B  C  D  
    granular plaques  granular plaques  granular plaques  granular plaques  
                
  HuMM  +* -  + +*  +* -  - -  
sCJD MM1  HuVV   - -  + -  - -  - -  
  HuMV  +* -  + -  +* -  - -  
                
  HuMM  - +*  + +  +* -  +* -  
sCJD MV1/2  HuVV   +* -  + +  +* -  +* -  
  HuMV  - +*  +* +  - +*  - +*  
                
sCJD MV2At  HuMM  - +*  + +  +* -  +* -  
  HuVV  +* -  + +  +* -  +* -  
  HuMV  - +*  +* +  - +*  - +*  
 
* Observed only in some animals 
 
BRAIN LEVELS 
 
 
 
 
 
 
 
 
 
  
A       B               C                         D 
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Figure 4. 8. PrP
TSE
 Immunohistochemistry (red) shows the presence of plaques along the hippocampus (arrowheads) 
and granular deposition in the ventral and lateral thalamic nuclei (arrows). The deposition in the thalamus parallels the 
presence of vacuoles (b,c). a,b: immunohistochemistry; c: Haematoxylin/Eosin staining. 
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Figure 4. 9. PrP
TSE
 immunohistochemistry in HuMM mice infected with the MV2At sCJD case shows the presence of 
plaques (a). The same plaques can be easily observed with the Haematoxylin/Eosin staining (b,c). 
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4.  4   PrP
TSE 
GLYCOTYPE 
The results of Western blot glycotyping of PrP
TSE
 extracted from the brains of transgenic mice and 
from the corresponding sCJD cases are shown in figure 4. 10. 
Transmission of the MM1 CJD case (A, lane 1) resulted in type 1 PrP
TSE
 formation in all three 
recipient mouse lines (A lanes 2, 3, 4). The molecular weight of the PrP
TSE
 in mice is slightly lower 
than that of the inoculum. The PrP
TSE
 in the three lines manteined the same glycoform ratio as the 
original inoculum (monoglycosylated > non-glycosylated > diglycosylated). 
Transmission of both the MV1/2 and the MV2At cases (B lane 1 and C lane 1) resulted in the 
presence of type 1 PrP
TSE
 in HuMM and HuMV mice (B, lanes 2 and 3; C lanes 2 and 3), and type 2 
PrP
TSE
 in HuVV mice (B, lane 4; C, lane 4). Again, the molecular weight of type 2 PrP
TSE
 in HuVV 
mice is slightly lower than that of type 2 PrP
TSE
 of inoculum. 
The three lines produced a similar pattern of glycoform ratio for both MV1/2 and MV2At inocula, 
but different from that observed in the human counterparts, with a higher presence of the 
glycosylated forms in mice. 
As described above, the CJD case MVx (D, lane 1) transmitted only to HuVV line, determining in 
these mice the deposition of a PrP
TSE
 type lacking the diglycosylated band (D, lane 2) similar to 
those found in the original CJD inoculum. In this case, the molecular weight of the PrP
TSE
 
accumulated in mice has a higher molecular weight than the human counterpart. The non-
glycosylated is more represented than the mono-glycosylated band in both inoculum and mice. 
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Figure 4. 10. Detection of PrP
TSE
 in human and mice brains by Immunoblot. A) MM1 case; B) MV1/2 case; C) MV2At 
case; D) MVx case. PrP
TSE
 was revealed by using the monoclonal anti-PrP antibody 3F4. The standards molecular 
weights are expressed in kiloDalton (marker: Magic Mark XP Western Protein Standard, Invitrogen). 
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5. DISCUSSION 
The design of this project was developed in order to obtain useful informations on a group of 
unusual, apparently sporadic, cases of CJD. These cases may be well truly sporadic, or derive from 
unrecognized interhuman, or rather zoonotic, episodes of transmission, and have an unknown 
potential to transmit to genetically susceptible individuals.  
Unique transgenic mouse lines expressing the three normal genotypes at position 129 of human PrP 
generated by gene targeting technique allow us to rule out possible misinterpretations about 
permissive genotype caused by the over-expression of the cellular prion protein commonly 
encountered with traditional transgenic approaches. 
The advantages of gene targeted transgenics, versus wild type mice (e.g. C3H line), for strain 
characterization, can be easily appreciated by comparing the short survival times and high attack 
rates presented here on transgenic mice injected with sCJD case MM1 (see summarized data in 
table 5. 1) with the long survival time and very low attack rate observed in C3H mice injected with 
the same inoculum (Nonno et al., 2006). 
The MV1/2 case was considered atypical because of a long clinical duration, a long phase of 
psychiatric and sleep disturbances, a relatively young age at onset and the presence of both types (1 
and 2) of PrP
TSE
. 
Although it is now recognized that the combination of type 1 and type 2 in the same brain, or even 
in the same brain area, is a relatively common event, the significance of this finding remains 
unclear. A possible hypothesis is that these patients are simultaneously infected by two independent 
prion strains as it often occurs in naturally affected sheep with scrapie. In this study we inoculated 
HuTg mice with a patient‟s brain sample containing only type 2 PrPTSE because we wanted to avoid 
any confusion due to the co-presence of type 1 and type 2 in our inoculum. However, it would now 
be of great interest to investigate whether a brain sample with mixed PrP
TSE
 types would produce in 
HuTg mice a pattern (attack rates, survival curves, lesion profiles, and PrP
TSE
 “signature”) similar to 
those observed with the pure type 2 PrP
TSE
 containing inoculum. 
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Patient MV2At presented very atypical clinical and laboratory features that the diagnosis in vita was 
thought to be either Alzheimer‟s or Pick‟s disease. He also had an unusual long clinical duration for 
a sporadic CJD. Thus, it would have been very difficult to make a correct diagnosis without the 
post-mortem examination of the brain. 
These two atypical cases (both MV1/2 and MV2At) transmitted with high efficiency to all three 
mouse lines, similarly to MM1 classical case, yet, at variance with the latter inoculum, they yielded 
an attack rate of 100% in HuVV mice with the shortest survival times of the whole study (table 5. 
1), suggesting that presence of PrP with 129 methionine reduces the susceptibility to the disease. 
Looking at the survival curves in figure 4. 3, the MM1 inoculum was faster in HuMM and HuMV 
than MV1/2 and MV2At inocula, while the opposite occurred in HuVV mice. At variance with 
MM1, during the transmission of type 2 cases, the 129 genotype affected both the susceptibility to 
the disease and the type of PrP
TSE
 deposited in the brain of diseased mice. In particular, the presence 
of at least one methionine at codon 129 promoted production of type 1 PrP
TSE
, whilst in valine 
homozygous mice, production of type 2 PrP
TSE
 was favoured (see table 5. 1 and figure 4. 10). This 
variability indicates that in type 2 transmissions the interaction between infectious strain and the 
host is more complex than in type 1 transmission, and that the acquisition of type 2 conformation of 
PrP
TSE
 is inhibited by the presence of a methionine residue at position 129. 
To better understand the mechanisms behind these observations it will be useful to establish the 
quantitative ratio between the two PrP allotypes in the heterozygous mice inoculated with the 
different human cases. This would explain if and how the 129 genotype and the infectious strain 
result in an allotype selective accumulation of PrP
TSE
 with methionine, or valine, at 129 and lead to 
a different propensity for conversion into a type 1 or type 2 conformation. 
The identical biochemical signature and pattern of PrP
TSE
 deposition within all three recipient 
mouse lines injected with MV1/2 and MV2At, and the similarities between survival curves in 
HuMM and HuMV (see figure 4. 3), as well as the lesions profiles in HuVV and HuMV mice (fig. 
4. 7), suggest that this two inocula may contain the same main strain. On the other hand, the slight, 
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though significant difference, among survival curves in HuVV (see figure 4. 3) and the differences 
observed in the lesion profiles in HuMM line infected with this two atypical cases (see figure 4. 7) 
indicate the opposite. To better characterize the two strains a second passage (mouse-to-mouse) of 
each isolate should be performed, with the aim of discriminating possible differences.  
Patient MVx had a clinical course of disease that was relatively characteristic for sporadic CJD, but 
presented a unique pattern of PrP
TSE
 by Western blot, which showed the complete absence of the 
diglycosylated band of the protein. A frozen brain sample of this patient was also intracerebrally 
inoculated in bank voles that developed the disease after an unusual long incubation period (about 
500 days) with a PrP
TSE
 pattern typical of that observed in animals inoculated with “classical” 
sporadic CJD patients bearing type 1 PrP
TSE
 (Zanusso et al., 2007). 
The atypical case MVx had very low transmission efficiency, with few mice (all valine 
homozygous) resulting PrP
TSE
 positive by Western blotting and very long survival times. 
Interestingly, neither histological lesions nor immunohistochemical PrP
TSE
 staining were observed 
in the brain of these animals, suggesting that the PrP
TSE
 did not form relevant aggregates, and do not 
trigger the classical cascade of events leading to cytotoxicity. This phenomenon could be 
attributable to a low infection titre in this inoculum, and/or to a reduced capability of this particular 
biochemical form of PrP
TSE
 to convert the host PrP
C
. This possibility is strengthened by the 
observation that the pattern of PrP
TSE
 in mice resembles that of patient‟s brain with respect to the 
absence of the diglycosylated band (see figure 4. 10) suggesting that this infectious strain has the 
capacity to convert only the mono and non glycosylated forms of PrP
C
.  
This unglycosylated dominant pattern, observed in the sporadic CJD MVx and in the recipient 
HuVV mice, differs from glycotypes encountered in sporadic CJD and variant CJD, whereas it is 
similar to that encountered in PRNP Thr183Ala and Val180Ile mutations (Grasbon-Frodl et al., 
2004) that result in allelic removal of the first consensus glycosylation site. However, differently 
from these mutations, the MVx case and HuVV mice show a normal representation of 
diglycosylated, monoglycosylated, and unglycosylated PrP
C
 isoforms (Zanusso et al., 2007; Bishop 
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et al., 2006) ruling out a constitutive glycosylation defect. This confirms that this PrP
TSE
 pattern is 
dictated by the infectious strain.  
For comparison (see table 5. 2), we use data produced by Bishop in the same line of HuTg mice (in 
yellow). The inocula taken from the brain of our sporadic CJD patient MV2At was compared with 
the “classical” sporadic CJD MV2 (from Bishop‟s panel) whereas our sporadic CJD MV1/2 and 
CJD MVx were compared with “classical” MV1 and MV2 (from Bishop‟s panel) since these 
inocula might possibly behave as “classical” type 1 or type 2. 
The attack rates and the type of PrP
TSE
 that the MV1/2 and MV2At sporadic CJD inocula produced 
in HuTg mice are much similar to those observed after transmission of the “classical” sporadic CJD 
MV2 patient (see table 5. 2) confirming the hypothesis that the broad phenotypic variations 
observed in sporadic CJD MV2 patients likely do not depend on the presence of different infectious 
strains, but from other, yet unidentified, factors. 
Regarding patient MV1/2, it is worth to mention that this inoculum gave a pattern much more 
similar to the “classical” sporadic CJD MV2, rather than to the CJD MV1, as suggested by the 
formation of PrP
TSE
 type 2 in HuVV mice (see table 5. 2). As we mentioned before, it would be 
interesting to inoculate in HuTg mice a brain sample containing mixed PrP
TSE
 type before drawing 
any strong conclusion on whether patients with double PrP
TSE
 type harbour one or two different 
prion strains. 
For what concern MVx case the very long survival time recorded in the positive mice and the 
pattern of PrP
TSE
, dissimilar to any other PrP
TSE
 observed in HuTg, strongly indicate that this case 
could represent a new strain of sCJD. 
These data highlight the usefulness of this model for the identification and studies of novel strains 
of human prion disease, relevant for the surveillance of the disease and public health, including the 
evaluation of potential human-to-human iatrogenic transmission.  
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   Table 5. 1.  Survival time, attack rate and PrP
TSE
 type for each case inoculated in the 
                       three transgenic lines. 
 
Inoculum from 
human sCJD 
Mice genotype 
Survival time 
(mean ± SD) 
Attack rate 
(% positive) 
PrP
TSE
 type 
MM1 
MM 402.7 ± 99.33 95% 1 
VV 453.0 ± 112.6 80% 1 
MV 415.1 ± 86.2 100% 1 
     
MV1/2 
MM 510.2 ± 62.2 81% 1 
VV 258.1 ± 21.1 100% 2 
MV 540.8 ± 98.7 89% 1 
     
MV2At 
MM 501.9 ± 88.2 100% 1 
VV 229.1 ± 17.6 100% 2 
MV 519.0 ± 100.8 100% 1 
     
MVx  
 
MM 511.9 ± 106.9 0% - 
VV 626 ± 28.6 22% as inoculum 
MV 453.6 ± 144.4 0% - 
Italic red, clinical but not PrP
TSE
 positive 
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               Table 5. 2.  Overall comparisons of different human inocula into HuTg mice carrying 
                                      the three different genotype at codon 129 of PRNP gene. 
 
sCJD 
HuMM HuVV  HuMV 
Rate PrP
TSE
 Rate PrP
TSE
 Rate PrP
TSE
 
MM1 95% 1 80% 1 100% 1 
MM1 100% 1 87% 1 100% 1 
MV1 94% 1 83% 1 89% 1 
MV2 91% 1 100% 2 89% 1 
MV1/2 81% 1 100% 2 89% 1 
MV2At 100% 1 100% 2 100% 1 
MVx 0% - 22% x 0% - 
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6. CONCLUSIONS 
The work described in this thesis validates the usefulness of our model of transgenic mice for the 
identification and the characterization of human prion strains, and to investigate the influence of the 
polymorphisms at codon 129 of PRNP on the development of the disease. 
Remarkably, these mice have the advantage over other “humanized” transgenics (Groschup and 
Buschmann, 2008) to express the human PrP at physiological levels and to develop the disease only 
when inoculated with human TSE infected brain tissues but not spontaneously as reported for other 
transgenics. 
In our study, a novel CJD strain originated form the MVx was likely isolated in HuVV mice, and it 
would be useful to perform a subsequent passage (mice-to-mice) to better characterize this strain, 
and to investigate whether PrP
TSE
 negative mice replicated infectivity, and eventually contain the 
same strain that replicated into HuVV mice. 
Concerning the other two atypical cases transmitted into our HuTg mice, a second passage would 
help to stabilize the strain and to have a reference for comparison to the MVx strain. 
Another important aspect to be highlighted regards the possibility to use this model of humanized 
mice to evaluate the potential iatrogenic risk of human -to -human transmission of CJD. Our data 
suggest that valine homozygous individuals might be susceptible to develop iatrogenic CJD if 
accidentally contaminated during surgical or dental procedures with prion diseases originated from 
all subtypes of sporadic CJD, including very atypical cases that would not affect methionine 
homozygous or heterozyghous subjects. 
In addition the data here presented might also explain why accidentally contaminated individuals 
develop CJD with a broad range of incubations periods (Graziano and Pocchiari, 2009; Brown, 
2007). Assuming that HuTg mice represent individuals carrying the three possible genotype at 
codon 129 on PRNP gene, from our data is possible to deduce that, depending upon the strain they 
have been exposed, each genotype would develop the disease with different incubation periods.  
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Although the idea that data obtained by inoculation of HuTg mice can be directly applied to what 
occurs in humans is intriguing, we have to be careful not to over-interpret these data, because it is 
likely that other factors differently expressed in humans than in mice might influence the 
susceptibility and the phenotypic features of the disease in the two species. 
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